- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
J&J’s antibiotic faces $800M lawsuit
Johnson & Johnson faces $800 million racketeering lawsuit over its antibiotic, Levaquin.
A new $800 million racketeering lawsuit alleges that Johnson & Johnson hid information about the devastating side effects of its antibiotic, Levaquin (Levofloxacin).
Plus, an FDA panel said last year that there are serious side effects of the entire class of antibiotics that Levaquin is a part of. Levaquin is prescribed to treat bacterial infections of the skin, sinuses, kidneys, bladder or prostate.
Related: Top 5 ways bacteria are becoming resistant to antibiotics
In the lawsuit, 5 plaintiffs allege that J&J and its Janssen unit deliberately mislabeled and misbranded Levaquin, playing down the harmful side effects of the drug for its own financial gain. They also listed former FDA Commissoner Margaret Hamburg in the suit, under the federal Racketeer Influenced and Corrupt Organizations (RICO) Act.
"These concerted efforts resulted in significant harm and/or death to consumers of Levaquin, including plaintiffs," according to the suit. The plaintiffs’ health problems have resulted in preventing them from obtaining work and they have accrued “enormous” medical expenses, according to the complaint.
Related: FDA greenlights combination antibiotic
The plaintiffs are asking to be awarded more than $120 million in compensatory damages and more than $750 million in punitive damages. The signficiant $800 million in damages stems from the fact that an estimated 60 million worth of Levaquin prescriptions were written during the time period in question.
In addition, J&J executives “unduly influenced” the FDA and Hamburg, the complaint states.
However, J&J defended its actions. "We … believe our actions regarding the medicine have been appropriate, responsible and in the best interests of patients," the company told FiercePharma in an email. "[W]e continually monitor the safety and efficacy of all our medicines and, in cooperation with the U.S. FDA and other health authorities, we update our product labels with new information so doctors and patients can make informed decisions."
Read more: FDA approves generic Levaquin
FDA Approves Pfizer’s Gene Therapy for Beqvez for Hemophilia
April 26th 2024Beqvez (fidanacogene elaparvovec) is priced at $3.5 million, which is on parity with Hemgenix, the first one-time therapy to treat adults with hemophilia B. Pfizer’s warranty will refund insurers and continue to provide coverage for patients if they change insurers.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
